Sarepta Therapeutics (SRPT) option implied volatility elevated
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
Evercore on Sarepta (SRPT) Post Stat News Article: 'probably sets up for the adcomm briefing documents and tone to be somewhat more negative'
April 13, 2023 10:39 AM EDTEvercore ISI analyst Gavin Clark-Gartner reiterated an Outperform rating and $149.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).
The analyst comments "The STAT article from this morning (HERE) is a must-read. To briefly summarize: the market had thought SRPTs... More
